Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and ... Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and commercial stage assets. It employs its LAT platform technology to create a portfolio of approved products. Its product candidates include Arimoclomol, KP1077IH, KP1077N and AZSTARYS. Arimoclomol is an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate, which is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), the Company's prodrug of d-methylphenidate (d-MPH). AZSTARYS is a prodrug for the treatment of ADHD in patients aged six years or older. Show more
CELEBRATION, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the...
CELEBRATION, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the...
CELEBRATION, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the...
MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra’s specialty pharmacy for dispense AmplifyAssist™, Zevra’s comprehensive patient support program...
FDA approval of MIPLYFFA™ and product launch cap third quarter filled with multiple commercial and clinical development milestones Zevra received rare pediatric disease Priority Review Voucher...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.33 | 3.93325387366 | 8.39 | 8.79 | 8.17 | 480513 | 8.44248782 | CS |
4 | -0.52 | -5.62770562771 | 9.24 | 9.76 | 8.17 | 456169 | 9.05196365 | CS |
12 | 1.41 | 19.2886456908 | 7.31 | 9.76 | 6.61 | 661212 | 8.38807723 | CS |
26 | 4.27 | 95.9550561798 | 4.45 | 9.76 | 4.2 | 817467 | 7.59326431 | CS |
52 | 3.82 | 77.9591836735 | 4.9 | 9.76 | 4.2 | 535879 | 7.14541201 | CS |
156 | 3.07 | 54.3362831858 | 5.65 | 9.76 | 3.89 | 394060 | 6.62128957 | CS |
260 | 3.07 | 54.3362831858 | 5.65 | 9.76 | 3.89 | 394060 | 6.62128957 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.